Currently , NUCRYST is engaged in its second Phase 2 clinical trial for a
cream formulation of NPI 32101, a powder form of NUCRYST's unique
nanocrystalline silver, for the treatment of atopic dermatitis.m . Brian Bosworth May 18

Mild-Moderate Crohn's Disease Dr.

urea bowel

NUCRYST is also
developing pharmaceutical products to address medical conditions that are
characterized by both infection and inflammation. until 5:00
p. The meeting showcases approximately 5,000
abstracts and hundreds of lectures on the latest advances in GI
research, medicine and technology.org
Salix Pharmaceuticals , Ltd. 9.

tract urethritis

According to IMS data, the top 10 dermatology topical products generated
$1.6 billion in US sales in 2004.
NUCRYST is also researching potential pharmaceutical products containing
NPI 32101 for use in the treatment of gastrointestinal disorders and, in
particular, has begun to explore its use to treat inflammatory bowel disease,
which includes ulcerative colitis and Crohn 's disease. Securities +
Exchange Commission. NUCRYST disclaims any intention or obligation to revise
forward-looking statements whether as a result of new information, future
developments or otherwise . All
patients reported decreased fecal urgency and complete resolution of
abdominal pain. until 5:00 p.

ulcers hives

NUCRYST Pharmaceuticals granted new patent for treatment of acne

Granted
by the US Patent and Trademark office, this is the third dermatology patent
issued to the company since 2004.
NUCRYST now holds patents covering all three indications.

NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures
and commercializes medical products that fight infection and inflammation
using its patented atomically disordered nanocrystalline silver technology.

colitis urticaria

S. Mean bowel frequency decreased from 14 daily to 5 daily.
on the day listed above.

urinary usher

NUCRYST now possesses 18 issued patents and 22 pending patent
applications in the United States as well as 60 corresponding patents and
38 corresponding pending patent applications in other major markets around the
world . 89% of the responders, including 3 patients who had been
refractory to treatment with ciprofloxacin dosed at 500 mg two times
daily, had complete remission and 11% reported a greater than 50%
response .

Digestive Disease Week (DDW) is the largest international
gathering of physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal surgery .
For full prescribing information on Xifaxan, please visit
www. These statements are just
predictions and are subject to risks and uncertainties that could
cause the actual events or results to differ materially. The reader is referred to the
documents that the Company files from time to time with the Securities
and Exchange Commission.

undulant uterine

urethra stomach

Smith + Nephew plc sell a range of advanced wound care products under their
Acticoat(TM) trade mark: Acticoat(TM) products incorporate NUCRYST's
SILCRYST (TM) coatings and are sold in over 30 countries. In this open label study patients were treated
with 400 mg of rifaximin two times daily for 14 days.

fibroids intestinal

Strengthened patent portfolio now covers top three dermatology diseases

WAKEFIELD, MA, March 8 - NUCRYST Pharmaceuticals
Corp. These three issued patents pertain to the
use of NUCRYST's unique silver for the treatment of acne, inflammatory skin
conditions such as atopic dermatitis, and hyperproliferative skin disorders
such as psoriasis .

Salix Pharmaceuticals Reports Digestive Disease Week Update; XIFAXAN Investigated in Pouchitis

XIFAXAN should not be used in patients
with diarrhea complicated by fever or blood in the stool or diarrhea
due to pathogens other than Escherichia coli. XIFAXAN should be
discontinued if diarrhea symptoms get worse or persist more than 24-48
hours and alternative antibiotic therapy should be considered .com
Salix trades on the Nasdaq National Market under the ticker symbol
"SLXP".

Please Note: This press release contains forward-looking
statements regarding future events.

urinary urea

Clinical trials may be suspended
or terminated at any time due to the actions of the FDA, other regulatory
authorities , our collaborators, or due to our own actions.

Business Editors/Biotech Writers
BIOWIRE2K

RALEIGH, N. today.m.
investigated the efficacy, tolerability and safety profile of
rifaximin 800 mg daily (400 mg BID) in the treatment of 10 patients
experiencing pouchitis. In
clinical trials, XIFAXAN was generally well tolerated.2% (vs. 10.

urethritis hives

S. No adverse events were reported.

colitis ulcerative

The company has developed
its nanocrystalline silver in a powder form for use as an active
pharmaceutical ingredient, referred to as NPI 32101.

Schedule information on upcoming poster presentations is provided
below:

TOPIC LEAD AUTHOR DATE/TIME/(a)

Small Intestinal Bacterial
Overgrowth in Irritable Bowel Dr. Cristiano Lauritano May 17
Syndrome Patients

Moderate to Severe Crohn's Disease Dr.7% (vs. 8.

uterus urea

m. placebo) were flatulence 11.2% (vs.salix.

tract urea

The poster is available for viewing from 8:00 a. 90% of the
patients responded to treatment with rifaximin, with mean time to
onset of response of 3 days and mean time to complete response of 7
days. Salix's strategy is to
in-license late-stage or marketed proprietary therapeutic drugs,
complete any required development and regulatory submission of these
products, and market them through the Company's 100-member
gastroenterology specialty sales and marketing team.7%), headache
9.

hives intestinal

"We now have patents covering use of our unique form of
nanocrystalline silver for the three therapeutic areas which comprise the
largest share of the US prescription dermatology market. Asher Kornbluth May 18

Small Bowel Bacterial Overgrowth Dr.m.
For more information please contact the Company at 919-862-1000 or
visit our web site at www.

hives inflammatory

- US Patent number 6 ,939,568 covers the use of NUCRYST's silver for
the treatment of inflammatory skin conditions such as atopic
dermatitis. The investigator has been requested to be present at the
poster from 12:00 noon until 2:00 p., headquartered in Raleigh, North
Carolina, develops and markets prescription pharmaceutical products
for the treatment of gastrointestinal diseases. 19.8%).

undulant ulcerative

"The pursuit of patent protection for the results of our ongoing
pharmaceutical discovery and development efforts is an important part of our
growth strategy," said Scott H.m.
Jointly sponsored by the American Association for the Study of Liver
Diseases (AASLD), the American Gastroenterological Association (AGA),
the American Society for Gastrointestinal Endoscopy (ASGE) and the
Society for Surgery of the Alimentary Tract (SSAT), DDW takes place
May 14-19, 2005 in Chicago. The most common
side effects (vs.com. Information on our web site is
not incorporated in our SEC filings.

uterine tract

and Canada securities laws or otherwise.

ulcers urticaria

Preclinical and formulation
research is being conducted on NPI 32101 for psoriasis and acne. Our clinical trial
could be delayed or prevented by several factors, including: delays in
identifying and reaching agreement on acceptable terms with prospective
clinical trial sites; insufficient quantities of study product; scheduling
conflicts with participating clinicians and clinical institutions; improper
enrollment practices resulting in protocol management problems and statistical
analysis problems; death of, or serious adverse effects experienced by, one or
more patients during the clinical trial even if the reasons are not related to
the study product candidate , including the advanced stage of the patient's
disease or medical condition; and other factors described under "Risk Factors"
in our Registration Statement on Form F-1 filed with the U.----Salix
Pharmaceuticals , Ltd.

uterus brucellosis

Pouchitis

Dr. Investigators are requested to be present at
their respective poster from 12:00 noon until 2:00 p.

XIFAXAN(TM) is licensed from Alfa Wassermann SpA.

ulcerative bacterial

Of this total , more than 70 per cent of
product sales were for the treatment of atopic dermatitis, psoriasis and acne. Results from
this trial are expected by the end of 2006. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Leonard Baidoo May 18

(a) Posters are available for viewing from 8:00 a.ddw.

tract hives

"

For dermatology indications , NUCRYST now holds the following patents:

- US Patent number 6,692,773 covers the use of NUCRYST's silver for
the treatment of hyperproliferative skin disorders and diseases such
as psoriasis.
In particular, the statement regarding the timing of the results of our
Phase 2 clinical trial may be a forward-looking statement for purposes of the
U. (NASDAQ: SLXP) today reported results of an
investigator-initiated trial of XIFAXAN(TM) (rifaximin) tablets 200 mg
that are being presented at Digestive Disease Week(R) 2005 (DDW)
today.1 %) and rectal tenesmus
7. These risks
and uncertainties include market acceptance for approved products,
management of rapid growth, intellectual property risks, and the need
to acquire additional products.

colitis bowel

Gillis , President + CEO, NUCRYST
Pharmaceuticals.
- US Patent number 7,008,647 covers the use of NUCRYST's silver for
the treatment of acne and rosacea.

Some of the statements above may constitute forward-looking statements
within the meaning of securities legislation in the United States and Canada.C.

fibroids peptic

(NASDAQ: NCST; TSX: NCS) today announced a new patent covering NUCRYST's
proprietary nanocrystalline silver for use in the treatment of acne.

Acticoat(TM) is a trademark of Smith + Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

XIFAXAN(TM)
(rifaximin) tablets 200 mg are indicated for the treatment of patients
(=>12 years of age) with travelers' diarrhea caused by noninvasive
strains of Escherichia coli.salix.

uterine digestive

Leonard Baidoo, Graduate Hospital, Philadelphia, PA, et al. For more information, please visit
www.3% (vs .2%), abdominal pain 7.